This is one of those videos that I watch, and I’m not sure whether to feel enraged at the way Pat Robertson and his co-host, Kristi Watts, conceptualize and discuss women, or to laugh at his utter confusion at the idea that women are sexual human beings, just like men (or boys, as he refers to them).
Pornographic photography in 1910s (Photo credit: Wikipedia)
So I just decided not to let this very confused elderly gentleman get under my skin, and instead I’ll try to clear up some misconceptions Robertson seems to have about women and humans in general.
In India there is a possible option for male birth control that could last up to ten years and is a quick, easy procedure that still allows men to have regular ejaculations. According to wired.com the new birth control method was developed by “maverick Indian scientist named Sujoy Guha.” The procedure is called reversible inhibition of sperm under guidance, or RISUG.
“(He) has spent more than 30 years refining the idea while battling bureaucrats in his own country and skeptics worldwide,” according to the Wired article. “He has prevailed because, in study after study, RISUG has been proven to work 100 percent of the time. Among the hundreds of men who have been successfully injected with the compound so far in clinical trials, there has not been a single failure or serious adverse reaction. The procedure is now in late Phase III clinical trials in India, which means approval in that country could come in as little as two years.”
If you really want to see what’s up with the procedure, there is a video of it on the wired.com article.
The procedure involves injecting a polymer into the vas deferens, the tube that carries ejaculate into the penis for emission, but due to the polymer’s pattern of negative/positive polarization it destroys the sperm.
The website techcitement.com has a an interesting article and graphic about the procedure and why it’s going to have a hard time coming to the United States. Basically the procedure is extremely inexpensive. Even the chemicals used in the polymer, styrene maleic anhydride and dimethyl sulfoxide, cost less than the syringe a doctor would use to give the treatment, according to the article. All of that means there probably isn’t a good profit for pharmaceutical companies.
The article at Wired.com reads, “Thanks to a novel collaboration between Guha and a San Francisco reproductive health activist, RISUG could soon be on the road to FDA approval in the US.”